Hideki Garren on rethinking multiple sclerosis care - EMJ GOLD

This site is intended for healthcare professionals

Continue

Hideki Garren on rethinking multiple sclerosis care

EMJ GOLD

Season 12: episode 2

This week, Isabel sits down with Hideki Garren, Senior Vice President and Global Head of Clinical Development, Neurology, Roche, to explore how our understanding of multiple sclerosis is changing and what that means for patients.

In the episode, Hideki reflects on his path into neurology and explores the shift in how multiple sclerosis is understood, from relapses to ongoing progression. He discusses the challenge of measuring this progression and the importance of better data, imaging and patient insight. Looking ahead, he shares a hopeful vision for slowing, stopping and ultimately preventing the disease.

Quickfire questions

Coming soon
Part 1: From curiosity to care
Coming soon
Part 2: Challenging old frameworks
Coming soon
Part 3: The future of MS

Guest bio

Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor’s degree from Caltech and an MD and PhD from UCLA.

Host:
Isabel O'Brien

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.